These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27997699)

  • 1. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
    García-Sanz P; Triviño JC; Mota A; Pérez López M; Colás E; Rojo-Sebastián A; García Á; Gatius S; Ruiz M; Prat J; López-López R; Abal M; Gil-Moreno A; Reventós J; Matias-Guiu X; Moreno-Bueno G
    Int J Cancer; 2017 Apr; 140(7):1551-1563. PubMed ID: 27997699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
    McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
    Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
    Marchiò C; De Filippo MR; Ng CK; Piscuoglio S; Soslow RA; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2015 May; 137(2):321-8. PubMed ID: 25701704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
    Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
    Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
    An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
    Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.
    Abal M; Planaguma J; Gil-Moreno A; Monge M; Gonzalez M; Baro T; Garcia A; Castellvi J; Ramon Y Cajal S; Xercavins J; Alameda F; Reventos J
    Histol Histopathol; 2006 Feb; 21(2):197-204. PubMed ID: 16329044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
    Leskela S; Romero I; Rosa-Rosa JM; Caniego-Casas T; Cristobal E; Pérez-Mies B; Gutierrez-Pecharroman A; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; Andrada E; Montes S; Pastor F; Gomez MC; López-Guerrero JA; Poveda A; Palacios J
    Am J Surg Pathol; 2020 Jul; 44(7):982-990. PubMed ID: 32384322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
    Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
    Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
    Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetic heterogeneity in undifferentiated endometrial carcinomas.
    Rosa-Rosa JM; Leskelä S; Cristóbal-Lana E; Santón A; López-García MÁ; Muñoz G; Pérez-Mies B; Biscuola M; Prat J; Esther O; Soslow RA; Matias-Guiu X; Palacios J
    Mod Pathol; 2016 Nov; 29(11):1390-1398. PubMed ID: 27491810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel molecular profiles of endometrial cancer-new light through old windows.
    Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low- and high-stage tumours.
    McHenry A; Devereaux K; Ryan E; Chow S; Allard G; Ho CC; Suarez CJ; Folkins A; Yang E; Longacre TA; Charu V; Howitt BE
    Histopathology; 2024 Oct; 85(4):614-626. PubMed ID: 38859768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
    Schultheis AM; Ng CK; De Filippo MR; Piscuoglio S; Macedo GS; Gatius S; Perez Mies B; Soslow RA; Lim RS; Viale A; Huberman KH; Palacios JC; Reis-Filho JS; Matias-Guiu X; Weigelt B
    J Natl Cancer Inst; 2016 Jun; 108(6):djv427. PubMed ID: 26832770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
    Rudd ML; Hansen NF; Zhang X; Urick ME; Zhang S; Merino MJ; ; Mullikin JC; Brody LC; Bell DW
    PLoS One; 2022; 17(1):e0251286. PubMed ID: 35081118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.